Dec 13, 2019
AI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in R&D related to rare neurological disorders. Under the deal signed, Healx Artificial Intelligence (AI) drug discovery platfo...
Read More...
Jan 20, 2017
Fragile X syndrome (FXS) is an inherited genetic condition that causes mental retardation, intellectual disability, and autism. Etiology of the disease includes the defect in the FMR1 gene located on the X-chromosome, which prevents the gene from properly synthesising a protein called the fragile X mental retardatio...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper